Bionano Genomics (BNGO) was recently below $6, and the firm is now attempting to expand to $10. So far, there has only been one successful effort, when the stock hit $7.19, but it failed. It has now decreased to $6.87.
The company announced that Jason Priar has joined the Bionano team as its Chief Commercial Officer. He has a deep understanding of how to break into clinical and research markets, including genetic diseases and cancer. Jason will oversee the commercial teams for Bionano’s platform and services companies in order to increase sales and market access with third-party payers.
According to the CEO of Bionano Genomics, Erik Holmlin, Jason can have a profound and positive impact on the future of Bionano. He knows how to increase income and gain market access from third-party payers and he has skills that the company needs to accelerate worldwide adoption of optical genome mapping (OGM) using our Saphyr® system.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.